insights_auto
Nega JAZZ tushdi 2,93%?
Batafsil oʻrganishchevron_right
JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
210,39 US$
arrow_downward
-2,93%(-6,36) 1K
210,39 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 13-okt, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoJAZZ tikeri uchun statistika yaratilmoqda...
Ochish
216,86 US$
Yuqori
216,86 US$
Past
209,34 US$
Bozor kapitali
13,66 mlrd
Oʻrtacha hajm
805,39 ming
Hajmi
812,59 ming
P/E koeffitsiyenti
14,39
52 haftalik eng yuqori
266,38 US$
52 haftalik eng past
128,80 US$
Aksiya boʻyicha daromad
14,63 US$
Beta
0,37
Muomaladagi aksiyalar
64,92 mln
Xodimlar soni
3 ming
Ochish
216,86 US$
Yuqori
216,86 US$
Past
209,34 US$
Bozor kapitali
13,66 mlrd
Oʻrtacha hajm
805,39 ming
Hajmi
812,59 ming
P/E koeffitsiyenti
14,39
52 haftalik eng yuqori
266,38 US$
52 haftalik eng past
128,80 US$
Aksiya boʻyicha daromad
14,63 US$
Beta
0,37
Muomaladagi aksiyalar
64,92 mln
Xodimlar soni
3 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Benzinga
·
1 kun oldin
Jim Cramer Gives Green Light To This Health Care Stock
Investing.com India
·
3 kun oldin
Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 10 October
Profil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Jazz Pharmaceuticals PLC haqida